The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer
Official Title: A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer (DTC)
Study ID: NCT04940052
Brief Summary: 150 adults patients with locally advanced or metastatic BRAFV600E mutation-positive, differentiated thyroid carcinoma who are refractory to radioactive iodine and have progressed following prior VEGFR targeted therapy will enter in the trial. Patients will be randomized in a 2:1 ratio to either dabrafenib plus trametinib or placebo. Patients will be stratified by number of prior VEGFR targeted therapy (1versus2) and prior lenvatinib treatment (yes versus no)
Detailed Description: This is a global, multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of dabrafenib plus trametinib in adult patients with locally advanced or metastatic BRAFV600E mutation-positive, differentiated thyroid cancer who are refractory to radioactive iodine and have progressed following prior VEGFR targeted therapy. After eligibility assessment, approximately 150 patients will be randomized in a 2:1 ratio to either dabrafenib plus trametinib or placebo. Patients will receive dabrafenib in combination with trametinib or placebo until disease progression as per RECIST 1.1 as determined by investigator and confirmed by BIRC or loss of clinical benefit as determined by investigator, death, unacceptable toxicity, pregnancy, withdrawal of consent, lost to follow-up or early termination of the study by the sponsor. Patients randomized in the placebo arm and for whom progression as per RECIST 1.1 is confirmed by blinded independent review committee and who meet the criteria will be given the option to cross over to the open label combination drug dabrafenib plus trametinib
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Northwestern University Med School, Chicago, Illinois, United States
Massachusetts General Hospital Dept of MGH 2, Boston, Massachusetts, United States
Novartis Investigative Site, Caba, Buenos Aires, Argentina
Novartis Investigative Site, Buenos Aires, , Argentina
Novartis Investigative Site, Rio De Janiero, RJ, Brazil
Novartis Investigative Site, Porto Alegre, RS, Brazil
Novartis Investigative Site, Blumenau, Santa Catarina, Brazil
Novartis Investigative Site, Sao Paulo, SP, Brazil
Novartis Investigative Site, Sao Paulo, , Brazil
Novartis Investigative Site, Calgary, Alberta, Canada
Novartis Investigative Site, Edmonton, Alberta, Canada
Novartis Investigative Site, London, Ontario, Canada
Novartis Investigative Site, Toronto, Ontario, Canada
Novartis Investigative Site, Fuzhou, Fujian, China
Novartis Investigative Site, Zhengzhou, Henan, China
Novartis Investigative Site, Wuhan, Hubei, China
Novartis Investigative Site, Nanjing, Jiangsu, China
Novartis Investigative Site, Nanjing, Jiangsu, China
Novartis Investigative Site, Xuzhou, Jiangsu, China
Novartis Investigative Site, Changchun, Jilin, China
Novartis Investigative Site, XI An, Shanxi, China
Novartis Investigative Site, Xi'an, Shanxi, China
Novartis Investigative Site, Chengdu, Sichuan, China
Novartis Investigative Site, Tianjin, Tianjin, China
Novartis Investigative Site, Kunming City, Yunnan, China
Novartis Investigative Site, Hangzhou, Zhejiang, China
Novartis Investigative Site, Beijing, , China
Novartis Investigative Site, Beijing, , China
Novartis Investigative Site, Changsha, , China
Novartis Investigative Site, Guangzhou, , China
Novartis Investigative Site, Shanghai, , China
Novartis Investigative Site, Tianjin, , China
Novartis Investigative Site, Tianjin, , China
Novartis Investigative Site, Hisar, Haryana, India
Novartis Investigative Site, Mumbai, Maharashtra, India
Novartis Investigative Site, Vellore, Tamil Nadu, India
Novartis Investigative Site, Hyderabad, Telangana, India
Novartis Investigative Site, Chennai, , India
Novartis Investigative Site, New Delhi, , India
Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Kuching, Sarawak, Malaysia
Novartis Investigative Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia
Novartis Investigative Site, Kuala Lumpur, , Malaysia
Novartis Investigative Site, Kuala Lumpur, , Malaysia
Novartis Investigative Site, Pulau Pinang, , Malaysia
Novartis Investigative Site, Ciudad de Mexico, Mexico CP, Mexico
Novartis Investigative Site, Monterrey, Nuevo Leon, Mexico
Novartis Investigative Site, Chihuahua, , Mexico
Novartis Investigative Site, Tainan, , Taiwan
Novartis Investigative Site, Taipei, , Taiwan
Novartis Investigative Site, Istanbul, TUR, Turkey
Novartis Investigative Site, Adana, , Turkey
Novartis Investigative Site, Ankara, , Turkey
Novartis Investigative Site, Ankara, , Turkey
Novartis Investigative Site, Edirne, , Turkey
Novartis Investigative Site, Hanoi, , Vietnam
Novartis Investigative Site, Hanoi, , Vietnam